Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

被引：497

作者：

Barker, AJ ^{[1
]}

Gibson, KH ^{[1
]}

Grundy, W ^{[1
]}

Godfrey, AA ^{[1
]}

Barlow, JJ ^{[1
]}

Healy, MP ^{[1
]}

Woodburn, JR ^{[1
]}

Ashton, SE ^{[1
]}

Curry, BJ ^{[1
]}

Scarlett, L ^{[1
]}

Henthorn, L ^{[1
]}

Richards, L ^{[1
]}

机构：

[1] AstraZeneca, Canc & Infect Res, Macclesfield SK10 4TG, Cheshire, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2001年 / 11卷 / 14期

关键词：

D O I：

10.1016/S0960-894X(01)00344-4

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compounds. ZD1839 has suitable properties for use as a clinically effective drug and shows activity against human tumours. In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed. (C) 2001 Elsevier Science Ltd. All rights reserved.

引用

页码：1911 / 1914

页数：4

共 10 条

[1] Structure-activity relationships for 4-anilinoquinazolines as potent inhibitors at the ATP binding site of the epidermal growth factor receptor in vitro [J].

Denny, WA ;

Rewcastle, GW ;

Bridges, AJ ;

Fry, DW ;

Kraker, AJ .

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1996, 23 (05) :424-427

[2]

Fry DW, 2000, ANTI-CANCER DRUG DES, V15, P3

[3] Epidermal growth factor receptor tyrosine kinase: Structure-activity relationships and antitumour activity of novel quinazolines. [J].

Gibson, KH ;

Grundy, W ;

Godfrey, AA ;

Woodburn, JR ;

Ashton, SE ;

Curry, BJ ;

Scarlett, L ;

Barker, AJ ;

Brown, DS .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (21) :2723-2728

[4] TYROSINE KINASE INHIBITORS .5. SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS FOR 4-[(PHENYLMETHYL)AMINO]-QUINAZOLINES AND 4-(PHENYLAMINO)QUINAZOLINES AS POTENT ADENOSINE 5'-TRIPHOSPHATE BINDING-SITE INHIBITORS OF THE TYROSINE KINASE DOMAIN OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR [J].

REWCASTLE, GW ;

DENNY, WA ;

BRIDGES, AJ ;

ZHOU, HR ;

CODY, DR ;

MCMICHAEL, A ;

FRY, DW .

JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (18) :3482-3487

[5]

SMAILL JB, 1995, J MED CHEM, V38, P1803

[6] New targets for therapeutic attack [J].

Wakeling, AE ;

Barker, AJ ;

Davies, DH ;

Brown, DS ;

Green, LR ;

Cartlidge, SA ;

Woodburn, JR .

[7] Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines [J].

Wakeling, AE ;

Barker, AJ ;

Davies, DH ;

Brown, DS ;

Green, LR ;

Cartlidge, SA ;

Woodburn, JR .

BREAST CANCER RESEARCH AND TREATMENT, 1996, 38 (01) :67-73

[8] EPIDERMAL GROWTH-FACTOR RECEPTOR TYROSINE KINASE - INVESTIGATION OF CATALYTIC MECHANISM, STRUCTURE-BASED SEARCHING AND DISCOVERY OF A POTENT INHIBITOR [J].

WARD, WHJ ;

COOK, PN ;

SLATER, AM ;

DAVIES, DH ;

HOLDGATE, GA ;

GREEN, LR .

BIOCHEMICAL PHARMACOLOGY, 1994, 48 (04) :659-666

[9] The epidermal growth factor receptor and its inhibition in cancer therapy [J].

Woodburn, JR .

PHARMACOLOGY & THERAPEUTICS, 1999, 82 (2-3) :241-250

[10]

WOODBURN JR, 1998, CELL MOL BIOL LETT, V3, P348

← 1 →